Clinical trial registry record

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 10, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05984927
Last registry update
September 10, 2026
Status
Active Not Recruiting
Phase
Phase 1, Phase 2
Sponsor
Elisigen, Inc.
Enrollment
20
Countries
United States, Canada
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
20
Population
ALL · 50 Years to 89 Years
Duration
2023-09-08 to 2030-01-01
Intervention
NG101 AAV gene therapy
Comparator
Not reported
Outcomes measured
Adverse Events — From Day 0 (pre-treatment) through Week 24; Ocular and Non -Ocular Adverse Events after week 24 — From Day 0 (pre-treatment) and through Weeks 52, 104, 156, 208 an…; Systemic Immunogenic Response — From Day -14 to Weeks 4, 8, 12, 24, 52, and 104; Systemic Immunogenic Response — From Day -14 to Weeks 4, 12, and 104; Systemic Immunogenic Response — From Day -14 to Day 7, and Weeks 2, 4, and week 12.; Systemic Immunogenic Response — From Day 0 (pre-treatment) to Weeks 24, 52, and 104; Signs of CNV (choroidal neovascularization) Activity — From Day -7 to Weeks 8, 24, 52, and 104; Central Subfield Thickness (CST) — From Day -7 to Weeks 24, 52, 104, 156, 208, and 260; Best Corrected Visual Acuity (BCVA) — From Day -7 to Weeks 24, 52, 104, 156, 208 and 260; Cumulative Number of Rescue Therapy Injections — Through Weeks 24, 52, 104, 156, 208, and 260
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON